| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1051870646 |
| P356 | DOI | 10.1038/SJ.BMT.1704346 |
| P698 | PubMed publication ID | 14676787 |
| P5875 | ResearchGate publication ID | 8958030 |
| P50 | author | Martha Skinner | Q130312309 |
| P2093 | author name string | J J Anderson | |
| R L Comenzo | |||
| D C Seldin | |||
| J L Berk | |||
| K Quillen | |||
| L M Dember | |||
| V Sanchorawala | |||
| D G Wright | |||
| R H Falk | |||
| K T Finn | |||
| P2860 | cites work | Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis | Q30656309 |
| Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report | Q33860770 | ||
| An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis | Q34435465 | ||
| Autologous stem cell transplantation for primary systemic amyloidosis | Q34661059 | ||
| The systemic amyloidoses | Q41596634 | ||
| Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease. | Q43592586 | ||
| AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation | Q44199471 | ||
| Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma | Q44200289 | ||
| Thalidomide alone or with dexamethasone for previously untreated multiple myeloma | Q44265645 | ||
| Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis | Q44388179 | ||
| Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy | Q44626189 | ||
| The epidemiology of AL and AA amyloidosis. | Q45230213 | ||
| Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients | Q47801564 | ||
| Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. | Q51033339 | ||
| Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. | Q52535343 | ||
| Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine | Q69974154 | ||
| Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma | Q70902037 | ||
| A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome | Q71123629 | ||
| A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine | Q73247899 | ||
| Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL) | Q73253020 | ||
| Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation | Q73948512 | ||
| The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement | Q74524530 | ||
| Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis | Q78160831 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| AL amyloidosis | Q4652470 | ||
| P304 | page(s) | 381-388 | |
| P577 | publication date | 2004-02-01 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial | |
| P478 | volume | 33 |
| Q83156992 | Amyloidosis |
| Q33304297 | An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis |
| Q43936667 | Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP. |
| Q57223555 | Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea |
| Q36215543 | Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience |
| Q37770112 | Cardiac amyloidosis: an approach to diagnosis and management |
| Q36574990 | Cardiac amyloidosis: shifting our impressions to hopeful |
| Q37899075 | Cardiac amyloidosis: the heart of the matter |
| Q37904673 | Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. |
| Q102152396 | Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis |
| Q43979184 | High dose therapy for light chain amyloidosis: can we reduce treatment related mortality further? |
| Q90841433 | High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review |
| Q38970608 | Immunoglobulin Light Chain Systemic Amyloidosis |
| Q51683327 | Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. |
| Q35081363 | Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial |
| Q53671959 | Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. |
| Q37570615 | Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis |
| Q82975012 | Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis |
| Q64360357 | Macrophage-Mediated Phagocytosis and Dissolution of Amyloid-Like Fibrils in Mice, Monitored by Optical Imaging |
| Q36484561 | Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? |
| Q38275212 | Natural history and therapy of AL cardiac amyloidosis |
| Q37045885 | Perspectives in treatment of AL amyloidosis |
| Q39159810 | Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. |
| Q46980729 | Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. |
| Q37995198 | Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis |
| Q37763504 | Systemic amyloidosis: a challenge for the rheumatologist |
| Q33288696 | Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. |
| Q53528767 | Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL). |
| Q57904876 | Treatment of AL amyloidosis with high dose therapy and autologous stem cell transplantation |
| Q89097365 | [Autologous peripheral blood hematopoietic stem cell transplantation for patients with primary light chain amyloidosis: experience of 31 cases in a single center] |
Search more.